These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26946483)

  • 21. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.
    Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V
    J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
    Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
    Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation.
    Battisti C; Formichi P; Radi E; Federico A
    J Neurol Sci; 2008 Apr; 267(1-2):120-4. PubMed ID: 18061619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.
    Labrie V; Brundin P
    J Innate Immun; 2017; 9(5):437-440. PubMed ID: 28866688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination for Parkinson's disease.
    Schneeberger A; Mandler M; Mattner F; Schmidt W
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S11-3. PubMed ID: 22166404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ELISA method to detect α-synuclein oligomers in cell and animal models.
    Lassen LB; Gregersen E; Isager AK; Betzer C; Kofoed RH; Jensen PH
    PLoS One; 2018; 13(4):e0196056. PubMed ID: 29698510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
    Zhang QS; Heng Y; Yuan YH; Chen NH
    Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trial Highlights: Targetting Alpha-Synuclein.
    McFarthing K; Simuni T
    J Parkinsons Dis; 2019; 9(1):5-16. PubMed ID: 30741694
    [No Abstract]   [Full Text] [Related]  

  • 31. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology.
    Kovacs GG; Wagner U; Dumont B; Pikkarainen M; Osman AA; Streichenberger N; Leisser I; Verchère J; Baron T; Alafuzoff I; Budka H; Perret-Liaudet A; Lachmann I
    Acta Neuropathol; 2012 Jul; 124(1):37-50. PubMed ID: 22370907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
    Thome AD; Standaert DG; Harms AS
    PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
    Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
    Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.
    Giasson BI; Jakes R; Goedert M; Duda JE; Leight S; Trojanowski JQ; Lee VM
    J Neurosci Res; 2000 Feb; 59(4):528-33. PubMed ID: 10679792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Role of Iron and Alpha-synuclein Interacting in Parkinson's Disease].
    Wang J; Song N; Xu HM; Jiang H; Xie JX
    Sheng Li Ke Xue Jin Zhan; 2015 Jun; 46(3):180-4. PubMed ID: 26521482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon.
    Sharrad DF; de Vries E; Brookes SJ
    J Comp Neurol; 2013 Feb; 521(3):657-76. PubMed ID: 22821666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
    Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
    Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.